Inclusion Criteria:
1. Written, informed consent obtained prior to any study-specific procedures.
2. Age older than 18 years.
3. Patients with refractory, relapsed, metastatic, advanced lung cancer confirmed by histology and biopsy.
4. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
5. Expected survival ≥ 12 weeks.
6. Not pregnant, and on appropriate birth control if of childbearing potential.
7. Initial hematopoietic reconstitution with
* neutrophils (ANC) ≥ 1,000/mm\^3;
* platelet (PLT) ≥ 100,000/mm\^3.
8. Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with
* serum creatinine ≤ 2×ULN;
* serum bilirubin ≤ 2×ULN;
* AST/ALT ≤ 2×ULN;
* ALKP ≤ 5×ULN;
* serum bilirubin. 2.0 is acceptable in the setting of known Gilbert's syndrome.
9. Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) test were negative.
Exclusion Criteria:
1. Have occurred in 5 years or are currently suffering from other cancers, except for cured cervical cancer, non-melanoma skin cancer and superficial bladder cancer.
2. Previous exposure to mouse CEA antibody.
3. Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study.
4. Minor surgical procedures within 2 days prior to Day 0 (including central venous access device placement for chemotherapy administration, tumor biopsies, needle aspirations).
5. Pregnant or lactating females.
6. Inadequate bone marrow function with
* absolute neutrophil count \< 1,000/mm\^3;
* platelet count \< 100,000/mm\^3;
* Hb \< 9 g/dL.
7. Inadequate liver and renal function with
* serum (total) bilirubin \> 1.5 x ULN;
* AST \& ALT \> 2.5 x ULN (\> 5 x ULN in patients with liver metastases);
* alkaline phosphatase \> 2.5 x ULN;
* serum creatinine \>2.0 mg/dl (\> 177 μmol/L);
* urine dipstick for protein uria should be \< 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate \< 1 g of protein/24 hr.
8. Serious active infection requiring i.v. antibiotics at during screening.
9. Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive.
